Arf6 inhibitors for the treatment of uveal melanoma
Arf6抑制剂用于治疗葡萄膜黑色素瘤
基本信息
- 批准号:8901672
- 负责人:
- 金额:$ 29.87万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-04-10 至 2017-04-09
- 项目状态:已结题
- 来源:
- 关键词:ADP-ribosylation factor 6AdultAgarAnchorage-Independent GrowthAnimal ModelAreaBiological AssayBody partCell Culture TechniquesCell LineCell ProliferationCellsClinical TrialsDataDevelopmentDiseaseDisease modelDrug KineticsEyeFutureGNAQ geneGenetic TranscriptionGrowthHumanIn VitroInflammationIntraperitoneal InjectionsLiverMEKsMalignant NeoplasmsMediatingMelanoma CellMethodsMitogen-Activated Protein KinasesMolecularMonomeric GTP-Binding ProteinsMusMutationNeoplasm MetastasisOrganPathway interactionsPatientsPharmaceutical PreparationsPhospholipase CPlayPositioning AttributePrimary NeoplasmProtein Kinase CProteinsRoleSignal PathwaySyndromeTestingTherapeuticTissuesToxic effectTranscription Factor AP-1UniversitiesUtahUveal MelanomaWNT5A geneWorkXenograft ModelXenograft procedurebasebeta catenincell behaviordrug developmenteffective therapyefficacy testingin vivoinhibitor/antagonistinterestknock-downmatrigelmelanocytemouse modelneoplastic cellnovelphase 1 studyphase 2 studypublic health relevancesmall moleculesuccesstumortumor growthtumorigenesis
项目摘要
DESCRIPTION (provided by applicant): Activating mutations in Gα proteins are the drivers of oncogenesis in numerous cancers. Therefore, identifying drugs that block the signaling pathways controlled by these mutations could have enormous therapeutic consequences. Uveal melanoma is a prototypical Gα-driven cancer in which about 80% of tumors have activating mutations in one of two Gα-encoding genes, GNAQ and GNA11. Although progress has been made in the treatment of primary uveal melanoma tumors, metastasis occurs in approximately 50% of patients and once the tumor has spread to other tissues and organs, usually the liver, no current treatments are effective and the disease is invariably fatal. Therefore, finding a treatment that reduces metastasis or can reduce tumor establishment or growth of metastatic uveal melanomas is of utmost importance, especially if the treatment also has therapeutic potential for several other cancers. Activating mutations in GNAQ and GNA11 control at least two major signaling pathways that are important for melanocyte transformation and uveal melanoma growth. These signaling pathways activate mitogen- activated protein kinase/extracellular signal-regulated kinases (MAPK/ERK) and YAP to control AP1- and YAP- TEAD-mediated transcription that leads to transformation and tumor growth. We and our collaborators at the University of Utah have identified the small GTPase ADP-ribosylation factor 6 (ARF6) as a primary immediate effector of constitutively activated GNAQ. Knocking down ARF6 expression or inhibiting its activation with the small molecule compound SecinH3 has the same effect as knocking down constitutively activated GNAQ. We have demonstrated that ARF6 knockdown inhibits the establishment and growth of tumors in an orthotopic xenograft mouse model of uveal melanoma and have preliminary data suggesting that small molecule inhibition of ARF6 likewise reduces tumor formation and growth. These results suggest that ARF6 inhibition may be an effective method for treating both primary and metastatic uveal melanoma. In this Phase I study, we will test our hypothesis by pursuing two aims. In Aim 1, we will determine whether novel ARF6 inhibitors can inhibit proliferation, anchorage-independent colony growth, and invasion of uveal melanoma cells. In Aim 2, we will test the efficacy of our inhibitors in our orthotopic xenograft model of human uveal melanoma. As noted above, Gα proteins play important roles in many cancers. Therefore, results from this Phase I study may have much broader implications for the treatment of multiple cancers. Success will place us in an ideal position to proceed to a Phase II study in which we will continue to examine the efficacy of these compounds in other animal models of uveal melanoma to show general applicability, while also performing pharmacokinetic and detailed toxicity studies. These Phase II studies will be necessary to obtain IND approval and allow for future clinical trials.
描述(由申请人提供):Gα 蛋白的激活突变是多种癌症发生的驱动因素。因此,识别阻断这些突变控制的信号通路的药物可能会产生巨大的治疗效果。葡萄膜黑色素瘤是一种典型的 Gα 驱动的癌症,其中约 80% 的肿瘤在两个 Gα 编码基因 GNAQ 和 GNA11 之一中存在激活突变。尽管原发性葡萄膜黑色素瘤的治疗已取得进展,但约 50% 的患者会发生转移,一旦肿瘤扩散到其他组织和器官(通常是肝脏),目前的治疗方法均无效,这种疾病总是致命的。因此,找到一种减少转移或减少肿瘤形成或转移性葡萄膜黑色素瘤生长的治疗方法至关重要,特别是如果该治疗方法还具有治疗其他几种癌症的潜力。 GNAQ 和 GNA11 的激活突变控制至少两条对黑色素细胞转化和葡萄膜黑色素瘤生长很重要的信号传导途径。这些信号通路激活丝裂原激活蛋白激酶/细胞外信号调节激酶 (MAPK/ERK) 和 YAP,以控制 AP1 和 YAP-TEAD 介导的转录,从而导致转化和肿瘤生长。我们和犹他大学的合作者已经确定小 GTP 酶 ADP-核糖基化因子 6 (ARF6) 是组成型激活的 GNAQ 的主要直接效应子。用小分子化合物SecinH3敲低ARF6表达或抑制其激活与敲低组成型激活的GNAQ具有相同的效果。我们已经证明,ARF6 敲低可抑制葡萄膜黑色素瘤原位异种移植小鼠模型中肿瘤的形成和生长,并且初步数据表明 ARF6 的小分子抑制同样会减少肿瘤的形成和生长。这些结果表明ARF6抑制可能是治疗原发性和转移性葡萄膜黑色素瘤的有效方法。 在本第一阶段研究中,我们将通过追求两个目标来检验我们的假设。在目标 1 中,我们将确定新型 ARF6 抑制剂是否可以抑制葡萄膜黑色素瘤细胞的增殖、不依赖贴壁的集落生长和侵袭。在目标 2 中,我们将测试我们的抑制剂在人类葡萄膜黑色素瘤原位异种移植模型中的功效。 如上所述,Gα 蛋白在许多癌症中发挥重要作用。因此,这项一期研究的结果可能对多种癌症的治疗具有更广泛的影响。成功将使我们处于进行 II 期研究的理想位置,我们将继续检查这些化合物在其他葡萄膜黑色素瘤动物模型中的功效,以显示普遍适用性,同时也进行药代动力学和详细的毒性研究。这些 II 期研究对于获得 IND 批准并允许未来的临床试验是必要的。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ALAN L MUELLER其他文献
ALAN L MUELLER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ALAN L MUELLER', 18)}}的其他基金
Depot formulation of a D-peptide HIV entry inhibitor
D 肽 HIV 进入抑制剂的长效制剂
- 批准号:
9408382 - 财政年份:2017
- 资助金额:
$ 29.87万 - 项目类别:
Depot formulation of a D-peptide HIV entry inhibitor
D 肽 HIV 进入抑制剂的长效制剂
- 批准号:
9329767 - 财政年份:2016
- 资助金额:
$ 29.87万 - 项目类别:
Treating Acute Lung Injury via Cytokine Signaling Blockade
通过细胞因子信号传导阻断治疗急性肺损伤
- 批准号:
8905970 - 财政年份:2015
- 资助金额:
$ 29.87万 - 项目类别:
ARF6 Inhibitors for Treatment of Acute Lung Injury
ARF6 抑制剂治疗急性肺损伤
- 批准号:
9347749 - 财政年份:2015
- 资助金额:
$ 29.87万 - 项目类别:
Therapeutic D-peptide Inhibitor of HIV Entry
HIV 进入的治疗性 D 肽抑制剂
- 批准号:
8764703 - 财政年份:2012
- 资助金额:
$ 29.87万 - 项目类别:
Therapeutic D-peptide Inhibitor of HIV Entry
HIV 进入的治疗性 D 肽抑制剂
- 批准号:
8467396 - 财政年份:2012
- 资助金额:
$ 29.87万 - 项目类别:
Therapeutic D-peptide Inhibitor of HIV Entry
HIV 进入的治疗性 D 肽抑制剂
- 批准号:
8597326 - 财政年份:2012
- 资助金额:
$ 29.87万 - 项目类别:
Slit2N for the Treatment of Viral Hemorrhagic Fever
Slit2N 用于治疗病毒性出血热
- 批准号:
8535980 - 财政年份:2012
- 资助金额:
$ 29.87万 - 项目类别:
Therapeutic D-peptide Inhibitor of HIV Entry
HIV 进入的治疗性 D 肽抑制剂
- 批准号:
9755320 - 财政年份:2011
- 资助金额:
$ 29.87万 - 项目类别:
Therapeutic D-peptide Inhibitor of HIV Entry
HIV 进入的治疗性 D 肽抑制剂
- 批准号:
9466753 - 财政年份:2011
- 资助金额:
$ 29.87万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 29.87万 - 项目类别:
Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 29.87万 - 项目类别:
Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 29.87万 - 项目类别:
Standard Grant
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 29.87万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 29.87万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 29.87万 - 项目类别:
Discovery Early Career Researcher Award
RUI: Evaluation of Neurotrophic-Like properties of Spaetzle-Toll Signaling in the Developing and Adult Cricket CNS
RUI:评估发育中和成年蟋蟀中枢神经系统中 Spaetzle-Toll 信号传导的神经营养样特性
- 批准号:
2230829 - 财政年份:2023
- 资助金额:
$ 29.87万 - 项目类别:
Standard Grant
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 29.87万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 29.87万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 29.87万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




